Tag Archives: Boris Peaker

Clearside Biomedical Received its Third Buy in a Row

After J.P. Morgan and Wedbush assigned a Buy rating to Clearside Biomedical in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Boris Peaker reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD) yesterday.

Cowen & Co. Believes MacroGenics (NASDAQ: MGNX) Still Has Room to Grow

In a report released yesterday, Boris Peaker from Cowen & Co. assigned a Buy rating to MacroGenics (NASDAQ: MGNX). The company’s shares opened today at $23.23, close to its 52-week high of $23.90. According to TipRanks.com, Peaker is a 4-star

Erytech Pharma SA Gets a Buy Rating from Cowen & Co.

In a report released today, Boris Peaker from Cowen & Co. assigned a Buy rating to Erytech Pharma SA (NASDAQ: ERYP). The company’s shares opened today at $30.30. According to TipRanks.com, Peaker is a 4-star analyst with an average return

Cowen & Co. Believes Urogen Pharma Ltd (NASDAQ: URGN) Won’t Stop Here

In a report released yesterday, Boris Peaker from Cowen & Co. assigned a Buy rating to Urogen Pharma Ltd (NASDAQ: URGN). The company’s shares closed yesterday at $41.56, close to its 52-week high of $44.63. Peaker commented: “URGN presented updates

Analysts Are Bullish on These Healthcare Stocks: CRVS, GLYC

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) and GlycoMimetics (NASDAQ: GLYC) with bullish sentiments. Corvus Pharmaceuticals Inc (NASDAQ: CRVS) In a report released yesterday,

Analysts’ Top Healthcare Picks: JNCE, UTHR

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jounce Therapeutics Inc (NASDAQ: JNCE) and United Therapeutics (NASDAQ: UTHR) with bullish sentiments. Jounce Therapeutics Inc (NASDAQ: JNCE) Cowen & Co. analyst